

# Criteria-Based Consultation Prescribing Program

## CRITERIA FOR DRUG COVERAGE

### Pregabalin Extended-Release (Lyrica CR)

#### Notes:

- QL: Yes
- <sup>1</sup> Formulary SNRIs: venlafaxine, duloxetine, desvenlafaxine
- <sup>2</sup> Formulary TCAs: nortriptyline, desipramine, amitriptyline
- <sup>3</sup> Wear-off of effect occurring after adjusting dose, frequency and/or timing

**Initiation (new start) criteria:** Non-formulary **pregabalin ER (Lyrica CR)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

#### **Diagnosis of Diabetic Peripheral Neuropathy (DPN) or Postherpetic Neuralgia (PHN)**

- Adequate trial of or contraindication, allergy or intolerance to all of the following:
  - Gabapentin
  - An SNRI<sup>1</sup>
  - A formulary tricyclic antidepressant (TCA)<sup>2</sup>
- Trial of immediate-release pregabalin with at least partial response but effect wears off<sup>3</sup> and unable to take another dose

**-OR-**

#### **Diagnosis of Restless Leg Syndrome (RLS)**

- Serum ferritin is greater than 100 ng/mL and %sat is greater than 45% within the past 3 months
- Trial of immediate-release pregabalin with at least partial response but effect wears off<sup>3</sup> during sleep

**Criteria for *current Kaiser Permanente members* already taking the medication who have not been reviewed previously and *new members* entering Kaiser Permanente already taking the medication who have not been reviewed previously:**

Non-formulary **pregabalin ER (Lyrica CR)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Trial of immediate-release pregabalin

**Continued use criteria for patients stable on the medication:** Non-formulary **pregabalin ER (Lyrica CR)** will continue to be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Patient continues to report sustained improvement in postherpetic neuralgia or restless leg symptoms, as documented by prescriber